Mandelic AcidvsTretinoin

Mandelic acid (152 Da, the largest common AHA) exfoliates through calcium chelation and corneodesmosome disruption like other AHAs, but its large molecular size results in slower, more even epidermal penetration with reduced risk of hot-spot irritation and stratum corneum over-exfoliation. Its phenyl ring confers partial lipophilicity, enabling penetration into the pilosebaceous unit and follicular infundibulum—unlike purely hydrophilic glycolic and lactic acids. Within pores, mandelic acid exerts mild comedolytic effects by disrupting keratinocyte cohesion in the follicular epithelium, similar to salicylic acid. It demonstrates antibacterial activity against Cutibacterium acnes (Propionibacterium acnes) through membrane disruption. Mandelic acid also inhibits tyrosinase and reduces melanosome transfer to keratinocytes, providing brightening benefits. This profile makes it particularly suitable for acne-prone skin, hyperpigmentation, and darker skin tones (Fitzpatrick IV–VI) where gentler exfoliation minimizes post-inflammatory hyperpigmentation risk.

Tretinoin binds nuclear retinoic acid receptors (RAR-alpha, beta, gamma), forming RAR/RXR heterodimers that bind retinoic acid response elements and activate gene transcription. This accelerates keratinocyte proliferation, reducing stratum corneum transit from ~28 to ~14 days. In the dermis, tretinoin stimulates fibroblasts and upregulates collagen I and III via TGF-beta while downregulating MMP-1, MMP-3, and MMP-9 that degrade the extracellular matrix. It normalizes melanocyte distribution and melanosome transfer. In acne, it prevents microcomedo formation by normalizing follicular keratinocyte differentiation and reducing corneocyte cohesion. RAR activation also modulates genes for epidermal growth factors and differentiation markers.